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Nearly two years since the start of the SARS-CoV-2 pan- 
emic, which has caused over 5 million deaths, the world con- 
inues to be on high COVID-19 alert. The World Health Orga- 
ization (WHO), in collaboration with national authorities, pub- 
ic health institutions and scientists have been closely monitor- 
ng and assessing the evolution of SARS-CoV-2 since January 2020 
 WHO 2021a ; WHO 2021b ). The emergence of specific SARS- 
oV-2 variants were characterised as Variant of Interest (VOI) and 
ariant of Concern (VOC), to prioritise global monitoring and re- 
earch, and to inform the ongoing global response to the COVID- 
9 pandemic. The WHO and its international sequencing networks 
ontinuously monitor SARS-CoV-2 mutations and inform countries 
bout any changes that may be needed to respond to the vari- 
nt, and prevent its spread where feasible. Multiple variants of the 
irus have emerged and become dominant in many countries since 
anuary 2021, with the Alpha, Beta, Gamma and Delta variants be- 
ng the most prominent to date. ( Table 1 ). 
nnouncement of new SARS-CoV-2 Variant of Concern - 
micron 
On Friday 26 November 2021, the WHO announced 
 WHO 2021c ) that a new SARS-CoV-2 Variant of Concern, named 
micron (initially named B.1.1.529), appeared to be increasing in 
lmost all of South Africa’s provinces, particularly Gauteng. The 
apid spread, especially among the younger age group, in Gauteng, 
outh Africa, has placed WHO and global health systems on 
igh alert. The SARS-COV-2 VOC was first reported to the WHO 
rom South Africa on 24 November, 2021. Cases of VOC Omicron 
ad also been identified in Botswana, Belgium, Hong Kong and 
srael. On 29 November, 2021, three days after the announcement 
y WHO, cases of VOC Omicron have been detected in Austria, 
ustralia, Belgium, Canada, Czech Republic, Denmark, France, 
ermany, Italy, the Netherlands and the United Kingdom. 
The global public health community applauds scientists in 
outh Africa and other countries which have reported the new 
OC for the speed with which they have identified, sequenced 
nd characterized SARS-CoV-2 strains, and their transparency and ttps://doi.org/10.1016/j.ijid.2021.11.040 
201-9712/© 2021 Published by Elsevier Ltd on behalf of International Society for Infectio
 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) penness in reporting quickly to WHO ( WHO 2021c ). Their SARS- 
oV-2 sequencing work has been exemplar ( Wilkinson et al. 2021 ; 
ao et al. 2021 ). As of November 28, 2021, 17:00 CET, 127 viral
enomes (VOC Omicron GR/484A) have been entered into the GI- 
AID databases ( GSAID 2021 ). Several receptor binding domains 
RBD) and N-terminal domains (NTD) mutations hypothesised to 
e associated with resistance to neutralizing antibodies and in- 
reased transmissibility are of concern. 
ravel bans to and from southern African countries – are they 
ecessary? 
Immediately following announcement by WHO of VOC Omi- 
ron, the European Union, Australia, Bahrain, Brazil, Canada, India, 
ran, Israel, Japan, Kuwait, Oman, Saudi Arabia, Switzerland, Thai- 
and, Turkey, the United Arab Emirates, the United States and oth- 
rs, imposed travel bans or travel restrictions to and from coun- 
ries in southern Africa reporting the Omicron variant, even includ- 
ng neighbouring countries. There is also the danger of the whole 
f Africa being lumped together in the same basket with a ban 
ll travel links. These political ‘knee-jerk’ decisions have generated 
idespread dismay and anger that South Africa and other African 
ountries are being unfairly treated. While throughout Africa there 
s pride that South Africa has been able to identify VOC Omicron 
nd rapidly share information, the South African scientists have 
elt the wrath of those within who anticipate another lockdown, 
urndown of the economy and further hardship, which they ex- 
erienced under previous COVID-19 lockdowns. This is extremely 
nfortunate. The consequential vilification of scientists in South 
frica due imposition of these travel bans is unwarranted. 
re Travel bans to limit global spread of VOC Omicron 
ustified? 
Travel bans go against WHO COVID-19 recommendations 
 WHO 2021d ; Petersen et al. 2020 ). In light of the huge air traffic
etween countries and continents, it is rather simplistic and naïve 
o assume that by imposing travel bans and travel restrictions on a 
ew countries reporting the new VOC Omicron, will prevent impor- 
ation of the virus, or limit establishment of significant clusters of us Diseases. This is an open access article under the CC BY-NC-ND license 
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Table 1 
WHO designated SARS-CoV-2 Variants of Concern (VOCs): (Adapted from WHO https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/) 
WHO designation (Date 
of Designation) Pango lineage GISAID clade Nextstrain Clade 
Additional amino acid 
changes monitored 
Country of origin of 
first documented 
samples 
ALPHA (18 Dec 2020) B.1.1.7 GRY 20I (V1) + S:484K 
+ S:452R 
Sept 2020 United 
Kingdom, 
BETA (18 Dec 2020) B.1.351 GH/501Y.V2 20H (V2) + S:L18F May 2020 South Africa 
GAMMA (11 Jan 2021) P.1 GR/501Y.V3 20J (V3) + S:681H Nov 2020 Brazil 
DELTA (11 May 2020) B.1.617.2 G/478K.V1 21A, 21I, 21J + S:417N + S:484K Oct 2020 India 
OMICRON (26 Nov 
2021) 
B.1.1.529 GR/484A 21K Nov 2021 South Africa, 
Hong Kong, Belgium, 
Israel 





























































































he Omicron VOC. The travel bans will no doubt have negative di- 
ect and indirect economic and social consequences on health sys- 
ems of African countries which are only just starting to recover 
rom the devastating effects of several COVID-19 lockdowns over 2 
ears. This is all the more important where the economy is fragile, 
uffering inflation, currency deflation and their hospitals lack funds 
o operate efficiently. In many of these African countries there is 
ittle evidence to show that they are contributing to the global 
urden of SARS-CoV-2 infections, but this could change. It is likely 
hat the VOC Omicron variant has already spread across the world, 
nd will continue to be detected in more countries across conti- 
ents. 
The WHO recommends that countries continue to apply a risk- 
ased and scientific approach when implementing specific travel 
easures and recommendations for reducing risk of acquisition 
r spread ( WHO 2021d ). However, over the past few months, in 
ieu of extensive roll out of COVID-19 vaccines, and reducing num- 
ers of COVID-19 cases and deaths, many countries have over the 
ast few months relaxed basic WHO recommended infection con- 
rol measures to reduce SARS-CoV-2 transmission, and communi- 
ies are becoming increasingly relaxed about the disease. With the 
mergence of Omicron VOC these countries now need to seriously 
onsider re-introducing WHO recommended basic public health 
nd social infection control measures such as wearing well-fitting 
asks, hand hygiene, physical distancing, improving ventilation of 
ndoor spaces, avoiding crowded spaces if unvaccinated. Countries 
hould also accelerate the COVID-19 vaccination programs. 
ajor Knowledge gaps on VOC Omicron 
Since its first appearance in November 2019, thousands of 
ARS-CoV-2 mutations have been identified from across the 
orld ( GISAID 2021 ), including Africa ( Inzauale et al. 2021 ; 
artin et al. 2021 ; Tao K et al. 2021 ; Wilkinson et al. 2021 ). These
ave had no major impact on protection induced by vaccines. Se- 
uencing of VOC Omicron shows approximately 50 mutations in 
ts genome, including more than 30 on the spike protein used 
o bind to host cells setting it apart from other known variants. 
his is a cause for concern since antibodies induced by vaccine 
r natural infection which neutralize the virus primarily target 
he spike protein. These may be potentially significant mutations 
hich could alter responses to vaccines, treatments and transmis- 
ibility. Other mutations appear similar to changes seen in other 
ariants associated with enhanced transmissibility. Whether VOC 
micron spreads faster, makes vaccines and drugs less effective, or 
hether it leads to more severe disease and deaths remains to be 
efined urgently. 
Many other questions arise regarding VOC Omicron and major 
aps in knowledge need to be filled. In South Africa, secondary 
ases from the epicentre in Gauteng need to be traced and fol- 
owed up and the epidemiology, transmissibility, pathogenesis, im- 269 une responses, and vaccine escape require urgent study. It re- 
ains to be proven that existing COVID-19 vaccines might be ef- 
ective at preventing serious disease due to VOC Omicron. Further 
nformation on the levels and types of antibodies and the role of 
-cells in preventing infections, reducing serious disease or deaths 
n vaccinated individuals requires definition. In many parts of the 
orld, HIV infection and other infections can synergize with the 
ARS-CoV-2 influencing COVID-19 management outcomes poten- 
ially influencing both pathogenesis of COVID ( Karim F et al. 2021 ; 
achega et al. 2021b ; Nachega et al. 2021c ). Plasmodium falci- 
arum infection induces cross-reactive antibodies to carbohydrate 
pitopes on the SARS-CoV-2 Spike protein ( Lapidus et al. 2021 ) and 
ould influence pathogenesis of COVID and perceptions of herd im- 
unity ( Ansumana et al. 2020 ) in many African countries. This re- 
uires further study. 
ow rollout of COVID-19 vaccines in Africa 
The explosive global spread of COVID-19 pandemic in 2020 gen- 
rated international consensus in principle, between the WHO, 
accine developers, governments, funders, donors and industry, 
ith agreement on the need to develop an effective COVID vac- 
ine and plans for fair and equitable rollout to all countries. Dur- 
ng the Covid-19 pandemic, these programs provided a model 
or the WHO and global partners to rapidly establish the COVID- 
9 Vaccines Global Access (COVAX) initiative to bridge the vac- 
ine gap and ensure rapid and equitable access to vaccines in 
oth high-income countries and low- and middle-income countries 
 WHO 2021e ). The African Vaccine Acquisition Task Team of the 
frican Union and the WHO-led COVAX consortium with its global 
artners had hoped to secure millions of doses of COVID-19 vac- 
ines to achieve 60% coverage in Africa by June, 2022 ( WHO 2021e ;
021f ; Nkengasong et al. 2020 ). This has been a major disappoint- 
ent ( WHO 2021g ). Richer nations focused on being the first to 
evelop and roll out COVID-19 vaccines to their own populations, 
ather than focus on what was best for all of humanity. The statis- 
ics for rollout of COVID-19 vaccines in Africa are appalling. Whilst 
n Europe an average of 60% of the population have received COVID 
accines, in Africa only 5-10% (24% in South Africa) of the popula- 
ion have received the first dose ( WHO 2021g ). Vaccine acceptance 
ates have also been low in some African countries. Tragically, con- 
erns regarding access to COVID-19 vaccines in Africa are similar 
o those raised during the HIV pandemic in the mid-1990s and 
arly 20 0 0s, when highly active antiretroviral treatment (HAART) 
as accessible in high-income countries but was too expensive for 
ollout in African countries ( Nachega et al. 2021a ) - a disparity that 
esulted in many preventable deaths in these high-burden settings. 
ddressing inequities 
Less than a fifth of people in Africa have been fully immunized 
gainst COVID-19, including millions of health workers and vulner- 















































ble populations. There remain many unvaccinated vulnerable pop- 
lations around the world, and every month thousands of people 
re still dying of COVID-19. The more SARS-COV-2 circulates and 
ransmits, the more VOCs evolve and further evolution of variants 
ay eventually lead to variants resistant to vaccines. One of the 
ontributing factors to emergence of VOCs is the low vaccination 
ates in parts of the developing world, particularly Africa. There 
emains an urgent need to get adequate and regular supplies of 
OVID-19 vaccines rolled out to, and accepted by all the peoples 
f Africa through strategic community education to increase vacci- 
ation rates and prevent severe disease and death. 
Given the continuing circulation of SARS-CoV-2 and emer- 
ence of VOC Omicron in Africa and elsewhere, vaccine devel- 
pment must adapt and evolve over time. It is re-assuring that 
n light of the emergence of VOC Omicron, vaccine manufactur- 
rs such as Moderna, Pfizer, AstraZeneca and Novavax, have in- 
icated that they have plans to adapt their current COVID-19 
accines and modify them accordingly. African governments also 
eed to take leadership and ownership of the emerging and re- 
merging infections agenda and invest more into developing their 
wn capabilities for manufacturing affordable and easily scalable 
accines. 
The emergence the VOC Omicron variant and its rapid spread 
eflects the legacy of wealthy nations’ failure to equitably distribute 
OVID-19 vaccines globally. This failure also contributes to pro- 
onging the pandemic, and has placed the whole world at contin- 
ed risk of COVID-19 and continuing impact on their economies. 
hether VOC Omicron, will turn out to be ‘a storm in a teacup’ or 
a lethal evolving threat to global health security’, its appearance 
early two years after its first discovery, is a stark reminder that 
he COVID-19 pandemic is far from over. Richer countries need to 
ake heed of the WHO slogan that ‘none of us is safe until all of us
re safe’ which has been highlighted ad nauseam . 
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